2013 Analysis of the European Pap Smear/HPV Market
This report presents a detailed analysis of the Pap Smear/HPV testing market in Europe (France, Germany, Italy, Spain, UK), including clinical significance and current laboratory practice; as well as five-year test volume and sales forecasts by country and market segment.
The report examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Contains 235 pages and 11 tables
The report examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Contains 235 pages and 11 tables
I. INTRODUCTION
II. PAP SMEAR/HPV WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
B. CURRENT AND EMERGING TECHNOLOGIES
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
PCR
DAP-PCR
Immuno-PCR
QC-PCR
CAR
DNA
HPA
LCR
NASBA
QBR
SDA
3 SR, and others
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
C. PERSONAL TESTING
FRANCE: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT
GERMANY: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT
ITALY: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT
SPAIN: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT
U.K. : TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT
II. PAP SMEAR/HPV WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
B. CURRENT AND EMERGING TECHNOLOGIES
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
PCR
DAP-PCR
Immuno-PCR
QC-PCR
CAR
DNA
HPA
LCR
NASBA
QBR
SDA
3 SR, and others
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
C. PERSONAL TESTING
FRANCE: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT
GERMANY: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT
ITALY: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT
SPAIN: TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT
U.K. : TEST VOLUME AND SALES FORECAST BY MARKET SEGMENT